BridgeBio Pharma vs BioCryst Pharmaceuticals
BBIO and BCRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BBIO and BCRX compare
BridgeBio Pharma is the larger company, worth 7.8 times as much as BioCryst Pharmaceuticals ($15.3B against $1.9B).
BridgeBio Pharma grew revenue faster over the last twelve months (167% versus 60.3% for BioCryst Pharmaceuticals).
BioCryst Pharmaceuticals scores higher on the StockData Score (9 against 3 for BridgeBio Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BBIO | BCRX |
|---|---|---|
| Size and price | ||
| Market cap | $15.3B | $1.9B |
| Share price | $78.30 | $7.61 |
| Change, 1 year | 18.2% | 6.0% |
| Change, 5 years | 83.6% | −36.0% |
| Beta (5Y) | 1.11 | 0.79 |
| Employees | 834 | 435 |
| StockData Score | ||
| Total score | 3 | 9 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 2 | 4 (better) |
| Performance score | 0 | 2 (better) |
| Health score | 1 | 2 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 16.1× | 2.0× (better) |
| P/FCF | – | 5.3× |
| FCF yield | −2.4% | 18.8% (better) |
| Growth | ||
| Revenue growth (TTM) | 167% (better) | 60.3% |
| Revenue growth, 5Y average | 127% (better) | 118% |
| Profitability | ||
| Gross margin | 94.3% | 97.9% (better) |
| Operating margin | −38.5% | −30.1% (better) |
| Net margin | – | −37.4% |
| FCF margin | −39.1% | 38.0% (better) |
| Financial health | ||
| Interest coverage | −7.1× | −3.8× (better) |
| Current ratio | 2.09 | 2.71 (better) |
| Altman Z-score | 0.16 (better) | −3.13 |
| Piotroski F-score | – | 7 |
| Dividends and buybacks | ||
| Buyback yield | 1.7% | – |
| Shareholder yield | 1.7% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 99.4% | 103% |
| Held by insiders | 35.6% | 1.9% |
| Insider net buying, 12 months | −$84.8M | −$4.1M (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 16.6% | 11.0% |
Go deeper
- BBIO stock overview
- BBIO income statement
- BBIO valuation and score
- BCRX stock overview
- BCRX income statement
- BCRX valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.